Chronic hepatitis B (CHB) is a major cause of liver disease worldwide despite the availability of effective vaccination. There are still more than 350 million people chronically infected with the hepatitis B virus (HBV)1 and progression of HBV-related liver inflammation to cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC) is estimated to result in up to 1.2 million deaths annually.

Additional Metadata
Keywords Hepatitis B, infectious diseases, inflammation, liver diseases, virology
Promotor H.L.A. Janssen (Harry)
Publisher Erasmus University Rotterdam
Sponsor Printing of this thesis was supported by F. Hoffmann-La Roche, Erasmus Universiteit Rotterdam, the department of Gastroenterology and Hepatology of the Erasmus MC Rotterdam, Nederlandse Vereniging voor Hepatologie, J.E. Jurriaanse Stichting, Merck, Sharp & Dohme B.V., Gilead Sciences, Innogenetics, Abbott, Boehringer Ingelheim BV and Virology Education B.V.
ISBN 978-94-6169-361-7
Persistent URL hdl.handle.net/1765/39715
Citation
Sonneveld, M.J. (2013, April 19). Host and Viral Predictors of Response to Antiviral Therapy in Chronic Hepatitis B . Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/39715